Figure 6
T cell/MDSC ratio at engraftment predicts the development of intestinal GVHD. (a) The ratios of T cells/CD11b+Gr-1+ cells at day 13 in the peripheral blood mononuclear cells (PBMCs) and the spleen were determined in the B6→F1 GVHD model. Individual values from the two independent experiments described in Figure 1 were considered and the data are presented as means±s.e.m. (b) The ratios of T cells/CD11b+Gr-1+ cells at day 7 in PBMCs and the spleen were determined in the B6→BALB.B GVHD model. The four independent experimental data sets described in Supplementary Figure S4 are considered and data are presented as means±s.e.m. (c) The ratios of T cells/CD11b+Gr-1+ cells at day 13 in PBMCs and the spleen were determined in the B6→F1 GVHD model. Recipients of MyD88KO TCD-BM plus WT T cells were injected with either 1.0 × 106 CD11b+Gr-1+ MDSCs isolated from WT or MyD88KO mice at days 3, 5, and 7 post transplantation. Individual data from two independent experiments described in Figure 4 were evaluated. Data are presented as means±s.e.m. (d) Information regarding the transplants recruited to the clinical study is shown and ratios of T cells/lineage-HLA-DR-CD11b+CD33+ MDSCs in PBMCs concerning the development of ⩾grade 2 intestinal GVHD are plotted at engraftment for 55 patients who underwent allo-HSCT with a myeloablative conditioning regimen. Patient characteristics are detailed in Supplementary Table 1. ANC; absolute neutrophil count; BMT, bone marrow transplantation; GVHD, graft-vs.-host disease; KO, knockout; MDSC, myeloid-derived suppressor cell; TCD-BM, T-cell depleted bone marrow; WT, wild type.
